ADRIANA GONZALEZ
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism HOUSTON, TX NPI 1003250796
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism TX Amgen Inc. All categories
General Payments — all program years on this page
$14,208.87
- Category: General Payments
- Program years: PY2018–2024
- Record count: 626
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $2,599.29 across 138 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,588.00 | 137 |
| Education | $11.29 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $329.01 | 18 |
| DEXCOM, INC. | $321.74 | 16 |
| Abbott Laboratories | $279.42 | 19 |
| Radius Health, Inc. | $269.50 | 22 |
| Lilly USA, LLC | $230.88 | 12 |
| Corcept Therapeutics | $185.14 | 11 |
| Novo Nordisk AS | $171.26 | 8 |
| Nevro Corp. | $153.85 | 2 |
| Medtronic, Inc. | $110.04 | 2 |
| Amneal Pharmaceuticals LLC | $72.51 | 4 |
| Bayer HealthCare Pharmaceuticals Inc. | $65.93 | 4 |
| Tandem Diabetes Care, Inc. | $57.66 | 2 |
| BETA BIONICS, INC. | $53.03 | 3 |
| Astellas Pharma US Inc | $47.66 | 2 |
| SANOFI-AVENTIS U.S. LLC | $42.16 | 2 |
| CeQur Corporation | $33.10 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $24.77 | 1 |
| PFIZER INC. | $22.92 | 1 |
| IBSA Pharma Inc. | $18.01 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.56 | 1 |
| Xeris Pharmaceuticals, Inc. | $17.11 | 1 |
| Acerta Pharma LLC | $16.88 | 1 |
| Kyowa Kirin, Inc. | $16.01 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $15.48 | 1 |
| OptiNose US, Inc. | $14.26 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.40 | 1 |
By program year
Records — PY2024 (138)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.